Work

353TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.455

Authors: S.A. Hurvitz, L.T. Vahdat, N. Harbeck, A.C. Wolff, S.M. Tolaney, S. Loi, N. Masuda, J. O'Shaughnessy, C. Dong, L. Walker, E. Rustia, V. Borges

Institutions: Ronald Reagan UCLA Medical Center, UCLA Medical Center, UCLA Jonsson Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, LMU Klinikum, Ludwig-Maximilians-Universität München, Johns Hopkins University, Dana-Farber Cancer Institute, Peter MacCallum Cancer Centre, Osaka National Hospital, Baylor University Medical Center, Seagen (United States), University of Colorado Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3088090224

FWCI: 0.092

Cites:

Cited by: 7

Related to: 10